Analyst Ratings for BridgeBio Pharma (BBIO)
BBIO Rating Summary
BBIO Price Target Summary
- Highest: $157.00 (Barclays)
- Lowest: $57.00 (Scotiabank)
- Average: $92.38
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$92.38 (+41.3%)
* Over Last 12-Mos
Rating Score: 9.6 / 10
Percentile Rank: 91%
Rating Score: 9.6 / 10
Percentile Rank: 91%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/28/2026 | Barclays | Eliana Merle | New Coverage | Overweight (N/A) |
157.00 (N/A) |
77.81 (65.36) |
-16% | Details |
| 1/6/2026 | Morgan Stanley » Updated 2/25/2026 |
Sean Laaman | New Coverage | Overweight (N/A) |
98.00 (96.00) |
78.24 (65.36) |
-16.46% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
